Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing real-world safety and economic evaluation of tislelizumab injection
ChiCTR2100042489Phase 4Recruiting
- Sponsor
- Union Hospital
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tislelizumab and sintilimab in cancer, classical Hodgkin lymphoma (cHL) and non-small cell lung cancer (NSCLC) (5 arms), sponsored by Union Hospital. Primary endpoints: Objective remission rate, Incidence of adverse drug reactions/adverse events and 2 more. Started Aug 2020; status: recruiting.
02
Drugs
tislelizumabsintilimab
03
Conditions
cancerclassical Hodgkin lymphoma (cHL)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100042489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042489.